Research is indicating benefits of rituximab (Rituxan) in treating lupus. Rituximab is an intravenously infused antibody that suppresses a particular white blood cell, the B cell, by decreasing their number in the circulation. B cells have been found to play a central role in lupus activity, and when they are suppressed, the disease tends toward remission. This may particularly helpful for people with kidney disease.

There is no permanent cure for SLE. The goal of treatment is to relieve symptoms and protect organs by decreasing inflammation and/or the level of autoimmune activity in the body. The precise treatment is decided on an individual basis. Many people with mild symptoms may need no treatment or only intermittent courses of anti-inflammatory medications. Those with more serious illness involving damage to internal organ(s) may require high doses of corticosteroids in combination with other medications that suppress the body's immune system.

Lupus is not necessarily life threatening when treated appropriately. Up to 90 percent of patients will have a normal life expectancy if they are followed closely by their doctor and receive proper treatment. (4,5) Lupus can, however, increase mortality rates because patients have a higher risk of heart disease, infection or complications such as inflammation of the kidney, or nephritis, says Francis Luk, MD, an assistant professor of rheumatology and immunology, Wake Forest Baptist Medical Center.

Inflammation associated with lupus and other autoimmune reactions largely stems from an overactive immune system and poor gut health. Leaky gut syndrome can develop in those with lupus, which results in small openings in the gut lining opening up, releasing particles into the bloodstream and kicking off an autoimmune cascade. This inflammatory process can wind up increasing the risk for many conditions, including heart disease or hypertension, weight gain, joint deterioration, and bone loss, just to name a few. (5)

The loss of self-tolerance is believed to be due to many hereditary and environmental factors and occurs when autoantigens are damaged, when they link with a foreign antigen, when the structure of a autoantigen is very similar to that of a foreign antigen (molecular mimicry), or when autoreactive T cells are not adequately controlled or are activated by nonspecific antigens. The changes in the appearance of the autoantigen or activation of autoreactive T-cells result in autoantigens being perceived as foreign. Inflammation and destruction of the tissues bearing the antigen occur because of the production of autoantibodies by B cells or the cytotoxicity of autoreactive T cells, which attack the autoantigens.
A large randomized trial that compared induction therapy consisting of oral mycophenolate mofetil with cyclophosphamide therapy in patients with lupus nephritis showed that mycophenolate mofetil was not inferior to cyclophosphamide. [132] The investigators suggested that mycophenolate mofetil was associated with both a trend toward greater complete remissions and a greater safety profile. [132] This study’s findings were confirmed with the large, international Aspreva Lupus Management Study (ALMS) trial. [133]
The principal immunoglobulin in human serum. Because IgG moves across the placental barrier, it is important in producing immunity in the infant before birth. It is the major antibody for antitoxins, viruses, and bacteria. It also activates complement and serves as an opsonin. As gamma globulin, IgG may be given to provide temporary resistance to hepatitis or other disease.
The mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases is to support research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases.
This gene encodes a member of the interferon regulatory factor (IRF) family, a group of transcription factors with diverse roles, including virus-mediated activation of interferon, and modulation of cell growth, differentiation, apoptosis, and immune system activity. Members of the IRF family are characterized by a conserved N-terminal DNA-binding domain containing tryptophan (W) repeats. Alternative promoter use and alternative splicing result in multiple transcript variants, and a 30-nt indel polymorphism (SNP rs60344245) can result in loss of a 10-aa segment.
Anti-dsDNA test:This is the protein directed against the double-stranded DNA, the material making up the genetic code.  This test is very specific for lupus, and can be used to determine a lupus diagnosis. One in every two people with lupus has a positive anti-dsDNA test.  The presence of this anti-dsDNA can indicate a higher risk of lupus nephritis, kidney inflammation that can occur with lupus. This test can confirm the need to closely monitor the kidneys.  Only half the people with lupus have a positive test, so a positive or negative test does not mean you have lupus.
The severity of lupus varies from mild to life threatening. Kidney problems and neurologic complications are more dangerous than the rashes, arthritis or other symptoms. After many years of having lupus, patients may develop hypertension (high blood pressure), accelerated atherosclerosis (plaque and fat build-up in the arteries), heart and lung diseases, kidney failure or osteoporosis. With proper treatment, the majority of people diagnosed with lupus have a normal life expectancy, but many will experience disabilities. Each patient will likely have his or her own specific pattern of symptoms and flares, but the disease can change over time.
“I tend to suffer from fatigue. About a year ago I made some changes to my diet; I cut out as many processed foods as I could and now start the day with porridge with blue/red fruits (i.e. blackberries, blueberries or cranberries). I now go to bed and get up at the same times every day and I started walking everyday too. I feel much better and sleep better too.”
If cyclophosphamide doesn’t work for patients with lupus nephritis, they now have the option of trying another drug, and more options are being tested in clinical trials, says Dr. Caricchio. For example, doctors may use CellCept (mycophenolate mofetil), Imuran (azathioprine), or Restasis (cyclosporine). Prograf (tacrolimus) may also be an effective option for lupus nephritis, according to study data appearing in the January 2016 edition of Autoimmunity Reviews. (5)

Affiliate Disclosure: There are links on this site that can be defined as affiliate links. This means that I may receive a small commission (at no cost to you) if you purchase something when clicking on the links that take you through to a different website. By clicking on the links, you are in no way obligated to buy.


Please Note: The material on this site is provided for informational purposes only and is not medical advice. Always consult your physician before beginning any diet or exercise program.

Copyright © livehopelupus.org

×